Vergent Bioscience’s breakthrough at STS 2024: VGT-309 enhances lung cancer surgery
At the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS2024), Vergent Bioscience, a Minneapolis-based clinical-stage biotechnology company, presented compelling new data about VGT-309, its investigational tumor-targeted fluorescent imaging agent. This revolutionary agent is designed to visualize primary and metastatic tumor tissue in the lung during surgery, potentially transforming the way lung cancer is […]